Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.81) by 39.51 percent. This is a 6.52 percent decrease over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $203.47 million which beat the analyst consensus estimate of $190.16 million by 7.00 percent. This is a 20.76 percent increase over sales of $168.49 million the same period last year.